Kronos Bio Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Deb Knobelman
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 0.3% |
| Management average tenure | less than a year |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being
Jun 20
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11Kronos Bio: Still Promising But Riskier Following ASCO Update
Jun 05Kronos Bio: Underestimated Drug Discovery Platform
May 06Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18CEO
Deb Knobelman (50 yo)
no data
Tenure
Dr. Deborah A. Knobelman, also known as Deb, Ph. D. has been Interim CEO and President of Kronos Bio, Inc. since December 3, 2024 and served as its Chief Financial Officer since June 03, 2024 until 2024. S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | no data | US$74.80k | 0.61% $ 337.2k | |
| Secretary & Director | no data | US$74.80k | 1.51% $ 840.7k | |
| President & Interim Chief Executive Officer | no data | no data | 0.27% $ 151.1k | |
| Chief Scientific Officer | less than a year | no data | 0.39% $ 215.8k | |
| Chief Administrative Officer | less than a year | no data | 0.34% $ 188.1k | |
| Vice President of Corporate Development & Investor Relations | 3.6yrs | no data | no data | |
| Senior Vice President of Clinical Development | 2.8yrs | no data | 0.32% $ 177.8k | |
| Senior Vice President of Drug Discovery & Pharmaceutical Development | 1.7yrs | no data | no data |
0.9yrs
Average Tenure
48.5yo
Average Age
Experienced Management: KRON's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Director | 7.5yrs | US$74.80k | 0.61% $ 337.2k | |
| Secretary & Director | 7.5yrs | US$74.80k | 1.51% $ 840.7k | |
| Director | 6.7yrs | US$1.76m | 21.02% $ 11.7m | |
| Scientific Advisory Board Chairman | no data | no data | no data | |
| Independent Chairman of the Board | 7.1yrs | US$117.20k | 1.13% $ 625.2k | |
| Independent Director | 4.3yrs | US$89.17k | 0.042% $ 23.3k | |
| Independent Director | 3.8yrs | US$88.70k | 0.019% $ 10.4k | |
| Independent Director | 3.1yrs | US$79.80k | 0% $ 0 | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Scientific Advisory Board Member | no data | no data | no data | |
| Independent Director | 1.8yrs | US$105.68k | 0% $ 0 |
5.5yrs
Average Tenure
53yo
Average Age
Experienced Board: KRON's board of directors are considered experienced (5.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:31 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kronos Bio, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhiqiang Shu | Berenberg |
| Robert Burns | H.C. Wainwright & Co. |
| Michael Yee | Jefferies LLC |